TNET:NYSETriNet Group, Inc. Analysis
Data as of 2026-05-27 - not real-time
$43.62
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
TriNet is trading around $43.6, well below its DCF‑derived fair value of roughly $59 and far under the industry’s average PE of 30, signaling a clear undervaluation. The company just delivered a Q1 EPS beat and reaffirmed its guidance, sparking a 10% price rally and underscoring momentum from recent earnings. Dividend yield sits at 2.73% with a modest 33% payout ratio, suggesting a sustainable income stream.
Technical indicators are mixed: the 20‑day SMA (≈42.35) sits just below the current price, MACD remains bullish, and RSI at 58 indicates room before overbought conditions. Support around $38.36 and resistance near $46.38 frame a neutral trend, while volatility is high (≈45% 30‑day) but beta is low (≈0.65), tempering market‑wide risk. Balance‑sheet pressure is notable, with debt‑to‑equity exceeding 1,100% and ROE only about 2.2%.
Given the valuation upside of roughly 16% and a sustainable dividend, the short‑ to medium‑term outlook leans toward buying, but long‑term exposure should be moderated due to leverage and modest profitability.
Technical indicators are mixed: the 20‑day SMA (≈42.35) sits just below the current price, MACD remains bullish, and RSI at 58 indicates room before overbought conditions. Support around $38.36 and resistance near $46.38 frame a neutral trend, while volatility is high (≈45% 30‑day) but beta is low (≈0.65), tempering market‑wide risk. Balance‑sheet pressure is notable, with debt‑to‑equity exceeding 1,100% and ROE only about 2.2%.
Given the valuation upside of roughly 16% and a sustainable dividend, the short‑ to medium‑term outlook leans toward buying, but long‑term exposure should be moderated due to leverage and modest profitability.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Recent EPS beat and reaffirmed guidance
- Bullish MACD and supportive dividend yield
- Price near short‑term support with neutral trend
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued relative to DCF fair value and industry PE
- Sustainable 2.73% dividend providing income
- Upside potential of ~16% based on valuation gap
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- High leverage (debt‑to‑equity >1,100%) raising balance‑sheet risk
- Low ROE and modest profitability
- Stable cash flow supporting dividend but limiting growth
Key Metrics & Analysis
Financial Health
Revenue Growth-4.90%
Profit Margin3.26%
P/E Ratio12.9
ROE217.81%
ROA4.19%
Debt/Equity1139.76
P/B Ratio38.3
Op. Cash Flow$357.0M
Free Cash Flow$252.3M
Industry P/E30.1
Technical Analysis
TrendNeutral
RSI58.7
Support$38.36
Resistance$46.38
MA 20$42.35
MA 50$39.79
MA 200$53.74
MACDBullish
VolumeStable
Fear & Greed Index92.34
Valuation
Fair Value$58.96
Target Price$50.60
Upside/Downside16.00%
GradeUndervalued
TypeValue
Dividend Yield2.73%
Risk Assessment
Beta0.65
Volatility45.78%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.